Compare CRTO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | KURA |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.8M | 841.6M |
| IPO Year | 2013 | 2015 |
| Metric | CRTO | KURA |
|---|---|---|
| Price | $17.16 | $9.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $34.00 | $25.56 |
| AVG Volume (30 Days) | 334.5K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.95 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $2,296,692,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | $5.54 | $106.37 |
| P/E Ratio | $149.13 | ★ N/A |
| Revenue Growth | ★ 27.65 | 25.24 |
| 52 Week Low | $15.58 | $5.45 |
| 52 Week High | $25.29 | $12.49 |
| Indicator | CRTO | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 38.45 |
| Support Level | $16.50 | $8.53 |
| Resistance Level | $19.51 | $9.82 |
| Average True Range (ATR) | 0.95 | 0.50 |
| MACD | -0.46 | -0.18 |
| Stochastic Oscillator | 2.42 | 15.38 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.